Effective November 6th, 2017, The Canadian Bioceutical Corporation (CSE:BCC) will be changing its name to MPX Bioceutical Corporation. Shareholders of the company approved the name change at the annual and special meeting of shareholders held on October 30, 2017.
“Our name change to MPX, mirrors the brand name of our well-established cannabis concentrate products, and reflects our strategic vision to become a dominant player in the recreational and medical cannabis markets in both the US and Canada. We believe this name change will resonate with the market, helping generate further traction for our brand and corporate presence,” said CEO, W. Scott Boyes. “Also, I would like to thank our new Board members for their affirmed commitment and support to MPX. This team brings significant and diverse sector-specific experience that further positions the company for success.”